Skip to main content
. Author manuscript; available in PMC: 2014 Aug 1.
Published in final edited form as: Mol Cancer Ther. 2013 May 30;12(8):1504–1514. doi: 10.1158/1535-7163.MCT-12-1197

Figure 5.

Figure 5

Vinblastine plus ABT-737 overcomes stroma-mediated drug resistance. Freshly-isolated lymphocytes from CLL patients were incubated with L4.5 stromal cells for 24 h. (A) CLL cells were then incubated with 0–10 μM ABT-737 with or without 1 μM vinblastine for 6 h. Cell lysates were analyzed for protein expression, PARP cleavage was measured by densitometry, and survival is expressed as the percentage uncleaved PARP (n=4). Vinblastine significantly enhanced apoptosis compared to ABT-737 alone, *p<0.05. (B) Untreated CLL cells incubated alone or with L4.5 stromal cells were analyzed for protein expression, with THP-1 cells serving as a positive control. Sample CLL53 was analyzed on a different western blot but the level of the control bands in THP-1 cells were comparable.